Our disruptive digital-first marketing engine has built strength across multiple social platforms. Our first strategic imperative is to build brand demand. Let me explain how each of these strategic imperatives underpinned our strength in fiscal '23. Over the past 4 years, I've provided proof points on how we've executed our 5 strategic imperatives and the growth that is driven. was again a top 10 shopping destination for teens and one of the only single brand sites among major retailers.
#Elf putty blush walgreens skin#
SKIN moved into the top 10 favorite skin care brands for the first time. We grew our share by 900 basis points versus a year ago and again held the #1 rank across all income groups.Į.l.f. remained the #1 favorite cosmetics brands amongst teens for the third time in a row. In Piper Sandler's latest semiannual teen survey, e.l.f. We are proud that out of nearly 4,200 public companies, we are only 1 of 4 with a Board that's at least 2/3 women and 1/3 diverse, underscoring our commitment to diversity and inclusion.Į.l.f. We continue to be recognized for our purpose and values as we strive to create a different kind of beauty company, one that is both purpose-led and results-driven. with well-recognized game changers such as NASA, Microsoft and OpenAI. We are the only beauty company on the list, putting e.l.f. In Q4, Fast Company named us to their annual Top 50 World's Most Innovative Companies. We're humbled by the recognition we continue to receive. has been celebrated for the power of our company, brands and disruptive marketing engine. SKIN consumption was up 55% in tracked channels, well above category growth rates. Q4 category trends were also strong, up 12% versus a year ago. We continue to be the fastest-growing top 5 brand by a wide margin. We grew our market share by 270 basis points, increasing our rank from #5 a year ago to the #3 brand for the first time. continued to significantly outperform the category, growing 64% in tracked channels. In Q4, the category grew 18% versus a year ago. We're encouraged by the continued strength we're seeing across the color cosmetics category. In Q4, we grew net sales by 78%, increased gross margin by approximately 470 basis points and delivered $21 million in adjusted EBITDA, up 66%. Q4 marked our 17th consecutive quarter of net sales growth. In fiscal '23, we grew net sales by 48% and adjusted EBITDA by 56%, well above our original expectations, and hitting major milestones by reaching over $500 million in net sales and over $100 million in adjusted EBITDA for the first time. Our value proposition, powerhouse innovation and disruptive marketing engine continue to fuel our performance. we have so much to be proud of in fiscal '23. I want to start by recognizing the e.l.f.
#Elf putty blush walgreens drivers#
Today, we will discuss the drivers of our exceptional fiscal '23 performance and outlook for fiscal '24. Thank you, KC, and good afternoon, everyone. With that, let me turn the webcast over to Tarang. Our earnings release contains reconciliations of the differences between the non-GAAP presentation and the most directly comparable GAAP measure. In addition, the company's presentation today includes information presented on a non-GAAP basis. Since many of our remarks today contain forward-looking statements, please refer to our earnings release and reports filed with the SEC where you'll find factors that could cause actual results to differ materially from these forward-looking statements. We encourage you to tune into our webcast presentation for the best viewing experience, which you can access on our website at. With me today are Tarang Amin, Chairman and Chief Executive Officer and Mandy Fields, Senior Vice President and Chief Financial Officer. I'm KC Katten, Vice President of Corporate Development and Investor Relations. Beauty's fourth quarter and fiscal '23 results. Thank you for joining us today to discuss e.l.f. William Bates Chappell MD Truist Securities, Inc., Research Division Presentation Susan Kay Anderson Analyst Canaccord Genuity Corp., Research Division Rupesh Dhinoj Parikh MD & Senior Analyst Oppenheimer & Co.
Olivia Tong Cheang MD & Research Analyst Raymond James & Associates, Inc., Research Division Oliver Chen MD & Senior Equity Research Analyst TD Cowen, Research Division Linda Ann Bolton-Weiser MD & Senior Research Analyst D.A. Wolfmeyer VP & Senior Research Analyst Piper Sandler & Co., Research Division Jon Robert Andersen Partner & Research Analyst William Blair & Company L.L.C., Research Division Beauty, Inc.Īndrea Faria Teixeira MD JPMorgan Chase & Co, Research DivisionĪnna Jeanne Lizzul Research Analyst BofA Securities, Research DivisionĪshley Elizabeth Helgans Equity Analyst Jefferies LLC, Research Divisionĭara Warren Mohsenian MD Morgan Stanley, Research Division
0 kommentar(er)
